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Introduction
Lung cancer is the most commonly diagnosed cancer and 
the most frequent cause of cancer death and unfortunately, 
the prognosis is poor (1). Most cases are non-small cell lung 
cancer (NSCLC). Accurate staging of NSCLC is crucial for 
allocation to surgical treatment, which is curative only in 
cases of localized disease. The recommended treatment of 
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Background: Several studies have reported the efficacy of esophageal ultrasound-guided fine needle 
aspiration (EUS-FNA) for the detection of metastases in the left adrenal gland (LAG) in patients with 
lung cancer. Currently we have only limited evidence based on small studies on the usefulness of EUS-B 
[endobronchial ultrasound (EBUS) scope into the esophagus] to provide tissue proof of suspected LAG 
metastases. The objectives of this study are to investigate feasibility, safety and diagnostic yield of EUS-B-
FNA in LAG analysis in patients with proven or suspected lung cancer. 
Methods: In two Danish hospitals, a systematic search in the electronic database for patients who 
underwent EUS-B-FNA of the LAG for suspected or proven lung cancer was performed retrospectively 
between January 1st, 2015 and December 31st, 2017. Computed tomography (CT), positron emission 
tomography-CT, endoscopy, pathology and follow-up data were acquired. 
Results: One hundred and thirty-five patients were included; the prevalence of biopsy proven LAG 
malignancy was 30% (40/135). A total of 87% (117/135) of EUS-B-FNA samples were adequate (i.e., 
containing adrenal or malignant cells). No complications were observed.
Conclusions: We present the largest cohort of patients ever reported showing that EUS-B-FNA of the 
LAG is a safe and feasible procedure and should therefore be used for staging purposes in patients with lung 
cancer and a suspicious LAG.
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disseminated NSCLC and of small cell lung cancer involves 
chemotherapy and radiation therapy. Staging is based on 
three components: T (the extent of the primary tumor), N 
(involvement of lymph nodes), and M (distant metastases). 
The clinical stage (cTNM) is determined before initiation 
of treatment and is based on any available information for 
example computed tomography (CT) and positron emission 
tomography-CT (PET-CT). 
The M component is subdivided into intrathoracic 
dissemination (M1a), a single extrathoracic metastasis 
(M1b), and multiple metastases (M1c) (2). The adrenal 
glands are common sites of lung cancer metastasis. 
Adrenal masses are found in up to 4–7% of patients with 
potentially resectable lung cancer (3). Approximately two 
thirds of these masses are benign adenomas (4). Therefore, 
pathological verification of a suspicious adrenal gland is 
mandatory for correct TNM classification and for correct 
treatment of the patient. Endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) and 
esophageal ultrasound-guided fine needle aspiration (EUS-
FNA) have high accuracy for demonstrating lung cancer 
and lymph node metastases (5,6). Furthermore, several 
studies have reported the efficacy of EUS-FNA for the 
detection of metastases in the left adrenal gland (LAG) in 
patients with lung cancer (7-13). The European Guidelines 
recommend endosonography for tissue verification from 
LAG lesions suspected of metastases (5). 
EUS-FNA can be performed either with the use of a 
conventional gastrointestinal ultrasound scope (EUS) or 
by using the EBUS-scope in the esophagus (EUS-B) (5). 
EUS-FNA is known to be able to provide tissue samples of 
lesions below the diaphragm including the LAG (12). EUS-
B-FNA has been shown to have equal diagnostic properties 
to EUS-FNA in diagnosing LAG lesions (13). However, 
EUS-B-FNA is a relatively novel technique. Therefore, 
the literature gives us limited access to experience. On this 
background we want to describe the largest cohort ever 
reported of patients with suspected lung cancer having the 
LAG biopsied by EUS-B-FNA.
Methods
In two centres (Department of Internal Medicine, Næstved 
Hospital, Denmark and Department of Internal Medicine, 
Zealand University Hospital, Roskilde, Denmark) a 
retrospective systematic search was performed in the 
hospitals’ electronic databases on all consecutive patients 
who underwent a tissue sample from the LAG with EUS-B-
FNA for suspected or proven lung cancer between January 
1st, 2015 and December 31st, 2017.
EUS-B-FNA sampling of the LAG was performed if a 
suspicious lesion was present, indicated by either increased 
metabolic activity at PET, or abnormal appearance at CT or 
EUS-B (if the LAG appeared enlarged, with loss of seagull 
sign or in any other way abnormal). Cytological results 
of the samples were registered and tissue samples were 
considered adequate when adrenal cells or malignant cells 
were demonstrated in the sample. 
For adequate samples with non-malignant diagnoses 
at cytopathological evaluation, the results of the biopsies 
were considered true-negative by at least 6 months follow 
up (clinical course and/or CT) both for patients with and 
without lung cancer if clinically relevant. 
Sensitivity of malignancy was defined as the number of 
samples in which EUS-B-FNA provided a diagnosis of any 
malignancy relative to the total number of targeted lesions 
that turned out to be malignant (14). By “worst-case” scenario, 
we understand a scenario were all patients with inconclusive 
samples or no follow-up are suffering from malignant disease. 
By “best-case” scenario, we understand a scenario were 
only patients with biopsy-proven malignancy are suffering 
from malignant disease.
Diagnostic yield was defined as the number of samples in 
which EUS-B-FNA provided a specific diagnosis (malignant 
or non-malignant) relative to the total number of samples 
performed with EUS-B-FNA (14).
Data were non-parametric and presented with median 
and range. Data were processed using SPSS. (IBM SPSS 
Statistics, version 25. Chicago, IL, USA).
The EUS-B procedure
EUS-B was performed as a part of the endoscopic work up 
combined with EBUS-TBNA according to the European 
guideline (5). Initially a bronchoscopy and an EBUS 
procedure according to a structured protocol as described 
by Konge et al. (11,15) were performed with the patient in 
a supine position under conscious sedation. Either a nasal 
or oral approach was used. Thereafter the EBUS endoscope 
was retracted from the trachea to a level just above the vocal 
cords and from this position turned slightly to the left and 
the back of the patient and advanced into the esophagus 
under gentle pressure while the patient was encouraged to 
swallow. Continuous ultrasound imaging was performed 
and the endoscope was advanced very carefully without 
pressure to a level below the diaphragm. Five milliliter 4% 
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Lidocaine was applied to the pharynx and larynx prior to 
the EUS-B procedure. A structured protocol was followed 
using an EUS assessment tool (EUS-AT) (11,15,16) with six 
landmarks identified in this order: the liver, the abdominal 
aorta, the LAG, lymph node station 7, station 4L and 4R. 
When an abnormal LAG was demonstrated, a biopsy was 
taken by introducing the needle through the biopsy channel 
of the endoscope. Power Doppler was used to prevent 
puncture of vessels. The tip of the needle was placed in the 
lesion under real-time ultrasonic guidance and the stylet was 
then removed. Suction was applied with a syringe and the 
needle was moved back and forth inside the lesion. At least 
two samples were taken and the aspirates were processed 
for both cytological smears and cell block analysis. EUS-B 
was performed with a flexible ultrasound bronchoscope 
(Olympus BF-UC180F or UC 180F, Olympus Medical 
Systems Europe, Ltd., Hamburg) in combination with a 
Hitachi ultrasound scanner (EUB 6500 or Hivision Preirus, 
model EZU-MT28-S1) with a linear scanning transducer. A 
19 G, a 22 G or a 25 G needle was used for the aspirations 
(ViziShot Flex 19 Gauge, 22 Gauge Olympus ViziShot 
and ViziShot 2. Olympus Medical Systems Europe, Ltd., 
Hamburg, Germany).
Ethics 
The study was a retrospective observational study without 
experimental procedures. The study does not fall under the 
jurisdiction of the scientific ethics system. The study was 
approved by the Danish Data Protection Agency. 
Results
A total of 135 patients with the LAG sampled with EUS-B-
FNA were identified in our systematic search. Demographic 
data and final diagnosis of work-up are shown in Table 1. 
At final diagnosis, 116 patients had a diagnosis of a 
malignant disease, mostly lung cancer. Of the 19 patients 
with non-malignant diagnoses after complete work up, at 
least 6 months follow up without subsequent finding of 
malignant disease was performed in all patients (10 followed 
with clinical course, 9 with clinical course and CT). No 
severe adverse events were recorded for any patients. 
A total of 87% (117/135) of the samples were adequate (i.e., 
containing adrenal cells or malignant cells) at cytopathological 
evaluation (Table 2): the prevalence of malignancy in the LAG 
was 30% (40/135). In 35 of these 40 patients, the malignant 
lesion was a metastasis from primary pulmonary cancer, in five 
patients the malignant lesion was a metastasis from an extra 
thoracic malignancy. No benign, specific diagnoses were made 
therefore diagnostic yield was 30% (40/135).
Of the remaining 77 patients with a non-malignant 
cytopathological finding, follow-up for the LAG lesion 
was not possible in 51 patients as final work-up showed 
disseminated malignant disease, and the patients were 
Table 1 Demographic data and final diagnosis of patients 
Variables Number
Number of patients, n 135
Gender: female 85 (63%)
Age, median [95% percentile] 69 [50–84]
Final diagnosis after complete work up
Primary pulmonary cancer 102 (76%)
NSCLC
Adenocarcinoma 62 (46%)
Squamous cell carcinoma 17 (13%)
NSCLC-NOS 10 (7%)
SCLC 12 (9%)
Large cell neuroendocrine carcinoma 1 (1%)
Metastasis from extra pulmonary tumor 10* (7%)
Lymphoma 4 (3%)
Non-malignant 19 (14%)
*, from colon: 3, upper gastrointestinal tract: 1, pancreas: 1, 
mammae: 1, uterus: 1; hepatocellular carcinoma: 1, malignant 
melanoma: 1, origin of primary tumor never found: 1. NSCLC, 
non-small cell lung cancer; NSCLC-NOS, non-small cell lung 
cancer not otherwise specified; SCLC, small cell lung cancer.
Table 2 EUS-B-FNA results of left adrenal gland sampling (n=135)
Variables Number
Cytopathological results of samples from the 
left adrenal gland
135
Adequate samples* 117 (87%)
Cytopathological diagnosis of adequate 
samples
Non-malignant 77 (66%)
Malignant 40 (34%)
*, tissue samples were considered adequate when adrenal cells 
or malignant cells were demonstrated in the sample.
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offered systemic, oncological treatment.
Follow-up of the LAG lesion was completed in 26 
patients without a diagnosis of cancer (clinical course 
n=13; clinical course and CT: n=13). Thus, in the best-case 
scenario, the negative predictive value (NPV) in patients 
without disseminated malignant disease plus 6-months 
follow-up was 100%. In a worst-case scenario where the 51 
patients without follow-up were considered false-negative, 
the NPV would be 34% (26/77).
Concerning the 18 inadequate samples, one patient had 
malignancy at re-EUS-B of the LAG, in 11 patients re-
sampling was irrelevant due to disseminated malignant 
disease, and in 6 patients, 6-months follow-up was without 
a diagnosis of cancer. 
Thus, sensitivity of malignancy was 39% in a worst-case 
scenario [40 malignant/103 (=40 malignant + 63 samples 
without follow-up)], and 98% in a best-case scenario 
[40/41 (=40 malignant at initial EUS-B + 1 malignant at re-
examination)].
The characteristics of LAG on CT, PET and EUS-B are 
shown in Table 3. Of the 44 patients with normal metabolic 
activity of the LAG on PET the lesion proved malignant in 
a single case.
Discussion
The main finding of our study is that EUS-B-guided biopsy 
from the LAG is a safe and feasible technique when used as 
a routine in the hands of chest physicians in the diagnosing 
and staging of patients with lung cancer. 
The current cohort of patients is by far the largest (n=135) 
ever reported, and the malignancy detection rate of EUS-B-
FNA was high. 
There is growing evidence of the value of EUS-B for 
mediastinal staging of lung cancer patients. However, we 
have very limited data concerning the role of EUS-B for 
staging of patients with lesions below the diaphragm. 
The LAG has been shown to be visualized and biopsied 
with EUS-B (13,17) in smaller cohorts. Crombag et al. 
found in a retrospective setting 9 cases with tissue 
biopsy (17) and in a prospective setting tissue biopsy from 
44 cases (13). Crombag et al. found that the success rate 
of EUS-B-FNA of LAG was comparable to conventional 
EUS-FNA (13). It should be noted that in these and the 
present study the length of the relatively short EBUS-
scope, compared to the EUS-scope, was not a limiting 
factor. Our data supports, with a large number of LAG 
samples, the ability of EUS-B to visualize and biopsy this 
structure.
In the analysis of sensitivity of malignancy and the NPV 
a group of samples from 51 patients it was not possible to 
perform the 6-month follow-up to show if the sample was 
true or false negative, since in all of these patients systemic 
oncological treatment of the disseminated disease was 
given. This relatively large number has a big influence on 
calculations. 
Calculations of sensitivity and NPV were performed both 
with these samples calculated as false negative, worst case 
scenario, (NPV 34%, sensitivity 39%) and in a best-case 
scenario (NPV 100%, sensitivity 98%). The true estimates 
must be placed somewhere in between. This weakness 
of the study is balanced by the strength of being able to 
demonstrate the value of the biopsies in a large consecutive, 
unselected cohort of patients in lung cancer work-up.
The sample adequacy of 87% is in line with earlier 
findings for EUS-B-FNA as Crombag et al. (13) found a 
sensitivity of 86% for LAG lesions.
The EUS endoscope tradit ional ly  used by the 
gastroenterologist is excellent for the left and lower para-
esophageal structures and structures below the diaphragm 
such as the LAG, whereas the EBUS endoscope provides 
access to structures close to the large airways (5,9-11). It is 
known that EUS-B-FNA with the EBUS endoscope in the 
esophagus is useful as a supplement to an endobronchial 
approach for additional sampling of mediastinal nodes 
Table 3 Characteristics of left adrenal gland at CT, PET and 
EUS-B
Variables Number
Number of samples 135
CT performed, n 135
LAG suspicious at CT* 114 (84.4%)
LAG not suspicious at CT 21 (15.6%)
Samples with PET performed, n 74
LAG suspicious at PET** 30 (40.5%)
LAG not suspicious at PET 44 (59.5%)
LAG in EUS-B description, n 110
LAG described suspicious on EUS-B 91 (82.7%)
LAG not suspicious on EUS-B 19 (17.3%)
*, CT and EUS-B suspicious when abnormal appearance (left 
adrenal gland enlarged,  loss of seagull sign or in any other way 
abnormal); **, PET suspicious when increased metabolic activity. 
LAG, left adrenal gland.
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(5,18-21) and the technique has also been shown to give 
assess to tissue samples from intrapulmonary tumors (22).
There are several technical advantages in the use of 
a conventional EUS-endoscope compared to EBUS-
endoscope for the esophageal approach, e.g. better stability 
in the stomach and the larger ultrasound device. The 
barriers of use of the EUS-endoscope in lung cancer work-
up are that most pulmonologists are not trained using the 
EUS-endoscope and that it requires another investment 
in the department already performing EBUS. Of these 
reasons, EUS-B-FNA is quickly gaining ground in Europe. 
Currently, one single endoscope that combines the features 
of the EUS scope mentioned with the EBUS scope designed 
for both esophagus and trachea does not exist.
Though inclusion in this study was consecutive, a 
limitation is a selection bias due to the retrospective 
design. Subsequent studies should include larger cohorts 
in a prospective multi-centre design including exclusively 
consecutive patients including prevalence of missed EUS-
B-FNA procedures due to inability to reach, visualize and/
or sample the LAG.
Our results  underl ine that  EUS-B enables  the 
pulmonologist to biopsy lesions in the LAG and thus 
EUS-B provides tissue proof of potential M1 lesions below 
the diaphragm.
In the future, interventional pulmonologists should be 
trained in both EBUS-TBNA (15) and EUS-B-FNA as 
recommended in the guidelines (5). Especially EUS-B-
guided biopsy from the LAG should be learned. 
Conclusions
LAG analysis in lung cancer patients can be performed 
safely with EUS-B-FNA. Therefore, its use should be 
considered in appropriate lung cancer staging cases. The 
single EBUS scope approach for both nodal and LAG 
staging provides obvious logistical and practical advantages.
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